Prefusion-Stabilized Fusion (F) Glycoprotein Vaccine Immunogens For Human Metapneumovirus
Human metapneumovirus (hMPV) infections have been shown as a common cause of upper and lower respiratory diseases such as bronchiolitis and pneumonia in young children, the elderly, and other immunocompromised individuals. Studies show that infections by the non-segmented negative strand RNA virus begin with attachment and entry of viral glycoproteins that mediate fusion with host cellular membranes. Like for the human respiratory syncytial virus (hRSV), a viral entry is initiated by the fusion (F) protein. Given its role in hMPV entry, the F protein has thus been a target for eliciting neutralizing antibodies and developm...
Source: NIH OTT Licensing Opportunities - January 26, 2021 Category: Research Authors: ott-admin Source Type: research
Hybridoma cell lines producing antibodies to RSV NS1
This technology provides a new set of hybridoma cell lines each expressing a single monoclonal antibody against human respiratory syncytial virus (RSV) nonstructural protein 1 (NS1). These antibodies have variously been shown to detect NS1 protein in an enzyme-linked immunosorbent assay (ELISA), Western blot assay, immunofluorescence microscopy of paraformaldehyde-fixed cells, and flow cytometry. The various antibodies can vary in their efficiency in each of these assays. This technology provides a unique set of qualified monoclonal antibodies against RSV NS1 protein which currently do not exist. These antibodies and cell ...
Source: NIH OTT Licensing Opportunities - January 25, 2021 Category: Research Authors: ott-admin Source Type: research
Combination therapies for covid-19 (sars-cov-2)
The coronavirus disease 2019 (COVID-19) is caused by a novel RNA enveloped coronavirus, SARS-CoV-2 when the virus enters human airway cells via an ACE2-mediated entry process. This entry pathway is facilitated by the cell surface heparan sulfate proteoglycan (HSPG), which enhances viral attachment to the cell surface. Researchers at NIDDK and NCATS have discovered a collection of FDA-approved drugs that can interfere with the entry of SARS-CoV-2. These drugs can be grouped into three classes based on the distinct steps in the viral entry pathway that they target. Specifically, Mitoxantrone, Raloxifene, and Piceatannol bind...
Source: NIH OTT Licensing Opportunities - January 25, 2021 Category: Research Authors: ott-admin Source Type: research
High-Throughput COVID-19 Diagnostic Test that Detects Both Viral and Host Nucleic Acid
The rapid worldwide spread and impact of COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has created a need for accurate, reliable, and readily accessible testing on a massive scale.NIEHS researchers developed a massively paralleled multiplexed screening method using next generation sequencing (NGS). This method uses sample-specific barcoded indexes that detect both SARS-COV-2 virus and the host ’s transcriptional response to infection simultaneously. By matching existing laboratory protocols for PCR-based sample processing, this assay is easily incorporated into existing CLIA-certified fa...
Source: NIH OTT Licensing Opportunities - January 11, 2021 Category: Research Authors: ott-admin Source Type: research
T-cell Receptors (TCRs) Specific for p53 Mutants
Tumor protein 53 (tp53 or p53) acts as a tumor suppressor by regulating cell division and DNA repair. Mutations of p53 reduce or eliminate its regulatory functions, contributing to cancer formation and progression. Such mutations in tumor protein p53 are expressed in a variety of human cancers such as colon, pancreatic, breast, and non-small cell lung cancer. Novel therapeutics are needed that specifically target p53 mutations, as small molecule inhibitors lack sequence specificity.T cell receptors (TCRs) are proteins expressed on the surface of T lymphocytes that can recognize peptide antigens from infected and malignant ...
Source: NIH OTT Licensing Opportunities - December 28, 2020 Category: Research Authors: ott-admin Source Type: research
RNASEH-Assisted Detection Assay for RNA
Several viral epidemics – such as the epidemics caused by H1N1 influenza virus, human immunodeficiency virus (HIV), Ebola virus, Zika virus, severe acute respiratory syndrome (SARS) virus, Middle East respiratory syndrome (MERS) virus and SARS-CoV-2 – have profoundly impacted global human health. Early identification o f infected and/or infectious persons and isolating them from the population are some of the most effective and evident measures to prevent human-to-human spreading. In addition, areas with low resources and infrastructure may benefit from this technique for the detection of any viral or non-viral pa thog...
Source: NIH OTT Licensing Opportunities - November 30, 2020 Category: Research Authors: ott-admin Source Type: research
Oxynitidine Derivatives Useful as Inhibitors of Topoisomerase IB (TOP1) and Tyrosyl-DNA Phosphodiesterase 1 (TDP1) for Treating Cancer
Topoisomerase 1B (TOP1) is an enzyme that relieves the torsional strain in DNA. To relieve the torsional strain, TOP1B cleaves one strand of DNA and forms a transient complex called a TOP1-DNA covalent cleavage complex (TOP1cc). TOP1 inhibitors – such as camptothecin – stabilize the TOP1cc and prevent relegation of the broken DNA which, when encountered by replication and transcription machinery, triggers cell death. The DNA damage generated by the TOP1cc can be repaired by several pathways, including tyrosyl-DNA phosphodiesterase 1 (T DP1) pathway.
Inhibitors of TOP1, including camptothecin (CPT), have long been re...
Source: NIH OTT Licensing Opportunities - November 30, 2020 Category: Research Authors: ott-admin Source Type: research
Leucine Zipper-bearing Kinase (LZK) -Targeting Degraders and Methods of Use
Leucine Zipper-bearing Kinase (LZK) has been identified as a novel therapeutic target in squamous cell carcinomas with 50% of head and neck squamous cell carcinoma (HNSCC) and lung squamous cell carcinomas (LSCC) patients showing amplifications or gains in LZK expression. Identifying successful therapies for the treatment of HNSCC or LSCC remains a significant unmet medical need. Researchers at the National Institutes of Health (NIH) have discovered a technology involving synthesized LZK-targeting PROTACs which are comprised of a LZK kinase inhibitor, linker, and a E3-ligase-binding warhead targeting VHL. The LZK PROTACs...
Source: NIH OTT Licensing Opportunities - November 30, 2020 Category: Research Authors: ott-admin Source Type: research
Triazole derivatives as p2y14 receptor antagonists
The technology describes the composition of small molecule compounds that are antagonists of the P2Y14 receptor. Also provided are methods of using the compounds, including a method of treating a disorder, such as inflammation, diabetes, insulin resistance, hyperglycemia, a lipid disorder, obesity, a condition associated with metabolic syndrome, and asthma, and a method of antagonizing P2Y14 receptor activity in a cell.NIDDKE-213-2015-0Development of P2Y14 receptor antagonist for treatment of disorders, such as:Inflammationdiabetesobesityasthmalipid disordermetabolic syndromer3425Nov 20, 2020Friday, November 20, 202062/233...
Source: NIH OTT Licensing Opportunities - November 20, 2020 Category: Research Authors: ott-admin Source Type: research
P2Y14 Receptor Antagonists Containing A Biaryl Core
The technology discloses composition of compounds that fully antagonize the human P2Y14 receptor, with moderate affinity with insignificant antagonism of other P2Y receptors. Therefore, they are highly selective P2Y14 receptor antagonists. Even though there is no P2Y14 receptor modulators in clinical use currently, selective P2Y14 receptor antagonists are sought as potential therapeutic treatments for asthma, cystic fibrosis, inflammation and possibly diabetes and neurodegeneration.NIDDKE-028-2018-0Development of P2Y14 receptor antagonist for treatment of disorders, such as:Inflammationdiabetescystic fibrosisasthmaneurodeg...
Source: NIH OTT Licensing Opportunities - November 20, 2020 Category: Research Authors: ott-admin Source Type: research
Identification of a New Human Monoclonal Antibody that More Potently Prevents Malaria Infection
Malaria is a major disease caused by a parasite transmitted through the bite of infected female mosquitoes. Globally, an estimated 214 million cases of malaria and 438,000 deaths from malaria occur annually, with chidren in African and South Asian regions being most vulnerable. Approximately 1,500-2,000 cases of malaria are reported in the United States each year, mostly in returning travelers from malaria- endemic countries. Among the international travelers, military personnel, diplomats, pregnant women, children and older individuals with weakened immune systems are more likely to be at risk of malaria infection and mor...
Source: NIH OTT Licensing Opportunities - November 13, 2020 Category: Research Authors: ott-admin Source Type: research
Dopamine D3 Receptor Agonist Compounds, Methods of Preparation, Intermediates Thereof, and their Methods of Use
Due to the large degree of homology among dopamine D2-like receptors, discovering ligands capable of discriminating between the D2, D3, and D4 receptor subtypes remains a significant challenge. The development of subtype-selective pharmaceutical small molecules to activate (agonists) signals regulated by D2-like receptors has been especially difficult. The inventors at the National Institute on Aging (NIDA) have recently synthesized a new generation of D3R selective agonists by applying a well-established bitopic molecular approach. Inventors were able to combine a primary pharmacophore (PP) with a secondary pharmacophor...
Source: NIH OTT Licensing Opportunities - October 27, 2020 Category: Research Authors: ott-admin Source Type: research
Composite Gels and Methods of their Use in Tissue Repair, Drug Delivery, and as Implants
Gel materials, such as hydrogel materials, typically lose mechanical strength as they swell. This property of gels limits their use in both biological (e.g., cartilage repair) and non-biological (e.g., engineering and construction sealing and repair) applications. Innovative gels in both medical and non-medical fields sorely are needed.Recent innovations in this space, from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), include self-reinforcing, composite gels. These gels comprise novel combinations of solvents and swellable crosslinked polymer particles. Exemplary solvent...
Source: NIH OTT Licensing Opportunities - October 27, 2020 Category: Research Authors: ott-admin Source Type: research
Simian T-Cell Lymphotropic Virus Strain Type 3 (STLV-3) Subtype D Variant, a Highly Divergent STLV-3, for Development of Diagnostics, Therapeutics, Vaccines and Research Tools
Simian T-cell lymphotropic viruses (STLV) are nonhuman primate retroviruses closely related to the human T-lymphotropic virus (HTLV). Types I, II, and III of HTLV have been found in humans and are believed to have originated from cross-species transmission of STLV from infected nonhuman primates. The HTLV viruses are known to cause leukemia, lymphoma, and neurological disorders.CDC researchers discovered a strain of simian T-cell lymphotropic virus type 3 known as STLV-3 subtype D variant. STLV-3 may be widespread in primates hunted in West-Central Africa, including the monkey Cercopithecus mona, which has a known geograph...
Source: NIH OTT Licensing Opportunities - October 26, 2020 Category: Research Authors: ott-admin Source Type: research
Rescue of AAV Production by shRNA Co-transfection
Recombinant adeno-associated virus (rAAV) vectors are proving to be a valid, safe and efficient gene transfer system for clinical applications. As most vectors utilize constitutive promoters, this results in transgene expression in the producer cell. Some of these transgene products can induce proapoptotic, cytostatic or other unknown effects that interfere with producer cell function. Therefore, this reduces the viral vector yield and is a major limitation when trying to characterize poorly described genes. NIDCR developed a method of expression of the transgene product during the vector production in the produce cell but...
Source: NIH OTT Licensing Opportunities - October 23, 2020 Category: Research Authors: ott-admin Source Type: research
